Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: A double-blind, randomized, placebo-controlled clinical trial

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 4, 2013, Pages 172-176

  Ghafari, Emel ^a   Fararouie, Mohammad ^a   Shirazi, Hamidreza Ghafarian ^a   Farhangfar, Arazm ^b   Ghaderi, Fateme ^c   Mohammadi, Ali ^a  

^a YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ALBERTA   (Canada)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Estrogen; PANSS; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CONJUGATED ESTROGEN; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; TRIFLUOPERAZINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MENTAL HOSPITAL; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84873572920     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.GHFA.01062013     Document Type: Article

References (43)

1. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Eur Arch Psychiatry Clin Neurosci 1991;241(1):65-68.
2. Riecher-Rössler A, Häfner H. Schizophrenia and oestrogens-is there an association? Eur Arch Psychiatry Clin Neurosci 1993;242(6):323-328.
3. Häfner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997;42(2):139-151.
4. Angermeyer MC, Kuhn L. Gender differences in age at onset of schizophrenia: an overview. Eur Arch Psychiatry Neurol Sci 1988;237(6):351-364.
5. Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W. First onset and early symptomatology of schizophrenia: a chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 1992;242(2-3):109-118.
6. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987;150:662-673.
7. Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry 1997;154(12):1641-1647.
8. Seeman MV. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986;73(6):609-617.
9. Seeman MV. Gender differences in schizophrenia. Can J Psychiatry 1982;27(2):107-112.
10. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007;37(10):1427-1436.
11. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen. Menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007;37(10):1427-1436.
12. Häfner H, Riecher-Rössler A, an der Heiden W, Maurer K, Fätkenheuer B, Löffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med 1993;23(4):925-940.
13. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20(3):247-252.
14. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 2001;49(1):47-51.
15. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, et al. Estrogen-a potential treatment for schizophrenia. Schizophr Res 2001;48(1):137-144.
16. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(6):1007-1012.
17. Louzã MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res 2004;66(2-3):97-100.
18. Bergemann N, Mundt C, Parzer P, Pakrasi M, Eckstein-Mannsperger U, Haisch S, et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res 2005;74(2-3):125-134.
19. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008;65(8):955-960.
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994.
21. Kay SR, Fiszbein, A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 1987;13:261-276.
22. World Medical Association, 2000. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net.
23. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994;20(1):203-214.
24. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V, et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet 2008;17(15):2293-2309.
25. Gogos A, Kwek P, Chavez CA, van den Buuse M. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A or 5-HT7 receptors. J Pharmacol Exp Ther 2009;333(1):218-227.
26. Hughes ZA, Liu F, Marquis K, Muniz L, Pangalos MN, Ring RH, et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol 2009;2(3):215-236.
27. Agius M, Hockings H, Wilson C, Lane D. Is estrogen neuroprotective? Psychiatr Danub 2009;21 Suppl 1:120-127.
28. Gattaz WF, Behrens S, De Vry J, Häfner H. [Estradiol inhibits dopamine mediated behavior in rats-an animal model of sex-specific differences in schizophrenia.] Fortschr Neurol Psychiatr 1992;60(1):8-16. German.
29. Häfner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res 1991;38(2):125-134.
30. Thompson TL, Certain ME. Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. Eur J Pharmacol 2005;511(2-3):121-126.
31. Bertrand PP, Paranavitane UT, Chavez C, Gogos A, Jones M, van den Buuse M. The effects of low estrogen state on serotonin transporter function in mouse hippocampus: a behavioral and electrochemical study. Brain Res 2005;1064(1-2):10-20.
32. Koldzic-Zivanovic N, Seitz PK, Watson CS, Cunningham KA, Thomas ML. Intracellular signaling involved in estrogen regulation of serotonin reuptake. Mol Cell Endocrinol 2004;226(1-2):33-42.
33. Gogos A, Van den Buuse M. Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1a receptor agonist 8-hydroxy-2- dipropylaminotetralin. J Pharmacol Exp Ther 2004;309(1):267-274.
34. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160(8):1522-1524.
35. Sribnick EA, Ray SK, Banik NL. Estrogen prevents glutamate-induced apoptosis in C6 glioma cells by a receptor-mediated mechanism. Neuroscience 2006;137(1):197-209.
36. Pawlak J, Brito V, Küppers E, Beyer C. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res 2005;138(1):1-7.
37. Singer CA, Rogers KL, Strickland TM, Dorsa DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 1996;212(1):13-16.
38. Yokomaku D, Numakawa T, Numakawa Y, Suzuki S, Matsumoto T, Adachi N, et al. Estrogen enhances depolarization-induced glutamate release through activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase in cultured hippocampal neurons. Mol Endocrinol 2003;17(5):831-844.
39. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984;41(2):157-161.
40. Herbison AE. Estrogen regulation of GABA transmission in rat preoptic area. Brain Res Bull 1997;44(4):321-326.
41. Herbison AE, Augood SJ, Simonian SX, Chapman C. Regulation of GABA transporter activity and mRNA expression by estrogen in rat preoptic area. J Neurosci 1995;15(12):83028309.
42. Favit A, Fiore L, Nicoletti F, Canonico PL. Estrogen modulates stimulation of inositol phospholipid hydrolysis by norepinephrine in rat brain slices. Brain Res 1991;555(1):65-69.
43. Martínez-Morales JR, Morales A, Marín R, Hernández-Jiménez JG, Acevedo A, Guerra B, et al. Estrogen modulates norepinephrine-induced accumulation of adenosine cyclic monophosphate in a subpopulation of immortalized luteinizing hormone-releasing hormone secreting neurons from the mouse hypothalamus. Neurosci Lett 2001;298(1):61-64.